Years ago, during isolation of pancreatic proteins Jorgensen et al. (1) noted a side fraction and thus discovered the pancreatic spasmolytic peptide. Further studies revealed that this peptide, along with two additional ones, formed a small family of cytoprotective peptides, later termed TFF (trefoil factor) family (2) to standarize the previous, somewhat confusing terminology. TFF1, TFF2 and TFF3 share a clover-like folding motif (the trefoil domain) as a hallmark of these peptides in vertebrates (3) but the evolutionary origin goes back to invertebrates (4) .
While at first, trefoils' activity was assigned to epithelial cells of the digestive tract and some carcinomas (for a most recent review, see 5) contributions from many research groups extended this setting and actually rather confused than clarified the picture. Several attempts to bring some order to this situation were made and a series of reviews present the current knowledge (e.g. 5-9). Next to their cytoprotective function the TFFs exhibit motogenic, anti-apoptotic, chemotaxic and neoplastic properties, and they participate in immune response, neural development and neusosensory activity. Therefore in this overview, several questions and some possible answers will be approached: a) what is the relation of the 3 family members? b) which expression patterns do they exhibit in normal and pathologic conditions? c) which functional properties are known for the TFFs? d) are cooperating factors known for the TFFs (receptors, binding proteins)? The unique trefoil folding structure ( fig. 1 ), at first suggested by Thim (3), is derived from disulphide bridges in a 1-5, 2-4, 3-6 pairing of cysteines. While TFF2 carries two trefoil domains, TFF1 and TFF3 display only one but also contain a seventh cysteine residue which is considered instrumental in allowing TFF1 and TFF3 to form peptide dimers (10, 11) . Whether these are functionally necessary in vivo is still a matter of investigation. Interestingly, all three genes are in very close neighborhood in all mammal species investigated (12) (13) (14) (15) and their promoters display common regulatory sequences (16, 17) . Moreover, the TFF domain is also found in further vertebrates {amphibians (Xenopus, Bombina) and fish (Cyprinus, Anguilla)} and this motiv has been noticed in additional species (Ciona savignyi, a tunicate; Caenorhabditis) (6, 4, 18) . This particular folding of the peptide renders it rather resistant to degradation by environment with low pH and by proteolytic enzymes (10), a possible adaptation of the peptides due to their specific expression patterns within the digestive tract: TFF1 and TFF2 are noted predominantly in the stomach, TFF2 also in pyloric and Brunner's glands and TFF3 in small and large intestine (5, 8) .
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The trefoil peptide family: small but versatile -from anti-apoptosis to neoplasia in the digestive tract TFF expression patterns Originally, TFF2 was isolated from porcine pancreas and TFF1 was noted in human breast carcinoma cells (1, 19) . Subsequent studies revealed the gastrointestinal (GI) tract as a major source of TFF expression (20, 21) . Several reports demonstrated the co-expression of specific TFFs with specific mucins and an interaction between these proteins may contribute to stabilization of the mucus layer (summarized in 8). Compared to TFF1 and TFF2, TFF3 is hardly present in the upper digestive tract (esophagus, stomach) but mainly expressed in goblet cells of the small and large intestine (22) . In addition to the GI tract, mainly mucus-secreting cells were found TFFpositive (salivary glands, respiratory and ocular tissues, prostate, ovaries) (reviewed in 5 and 8). Furthermore, TFFs were noted in liver, gall bladder, brain and the auditory organ (23) (24) (25) (26) . The first indication that TFFs were participating in mucosal regeneration came from the observation of aberrant expression patterns in inflamed GI tisues (27) . Many animal and human pathologies connected with the GI tract showed altered TFF expression patterns (summarized in 5). Upon experimental injury, an immediate response was the onset of increased TFF expression, here demonstrated in mouse stomach ( fig. 2) (28) . Also, in several carcinomas, aberrant TFF expression was reported and discussed as a possible tumor marker (reviewed in 29). The situation in malignant cells, however, is not uniform: in some cases, like pancreatic carcinoma, the TFF1 level is increased (30) , in stomach cancer it is found down-regulated (31) . The development of adenomas and adenocarcinomas in Tff1 knock-out mice prompted the authors to call tff1 a tumor suppressor gene (32) . Deleting tff2 and tff3 in mouse models, however, did not result in immediate malignancy. The tff3 knock-outs displayed colonic damage upon induction (by chemicals or radiation) (33) and the mild tff2 knock out phenotype was only noted when gene activity was scrutinously investigated (34) .
Functional properties
The numerous data collected for the function of TFFs suggest, at least in vitro, a multitude of activities. Their contribution to proliferation, migration, anti-apoptosis, angiogen- esis and interaction with mucins obviously connects them with wound healing but also carcinogenesis, as discussed in many publications and all reviews cited above. In addition, TFFs seem to interfere with inflammatory processes and innate immunity responses. Promoter sequences of all 3 tFF genes contain multiple regulatory motifs and expression control by transcription factors and cytokines leads to up-or down-regulation depending on the cell type and physiologic conditions. Interestingly, deletion of tff1 also leads to decrease of tff2 expression (32) and the tff3 knock-out mouse displays reduced tff1 and tff2 levels.
. This intricate regulatory set-up can possibly explain the multitude of different expression patterns, and, in addition to a variety of TFF interacting factors, the multiple functionalities reported. The vast majority of functional data however mirror in vitro studies and the factual physilogical role of TFFs is still awaiting a solid comprehesive description. Moreover, if TFFs as sectered peptides should contribute to cellular processes, an entry to the signalling pathway is expected. So far, all efforts to find a TFF receptor had been in vain (36, 37).
TFF interactions
While receptor molecules would be one class of factors interacting with the TFF family the suspected mucin-TFF networking suggests a secong group of proteins. In fact, co-expression of specific mucins with specific TFFs had been reported many fold (e.g. review 8) and binding of mouse tff1 to Muc2 and Muc5 was demonstrated with the aid of the yeast-two-hybrid system (38). Using a fusion-peptide approach, a different protein (GKN2) was found to interact with TFF2 and as it turns out, it is homologous to TFIZ1 reported to bind TFF1 (39; 40) . Another protein, CRP-ductin, was shown to bind to TFF2 (36). Ductin might be a part of the innate defense by agglutinating bacteria via surfactant protein D. Interestingly surfactant proteins share amino acid homologies with GKN2 suggesting such complexes with TFFs may play a role in the innate immune system. Actually, tff2 deleted mice show alterations in a set of genes involved in innate immunity (34) . Maybe not surprisingly, dimeric TFF1 was demonstrated to bind to Helicobacter pylori being a prerequisite for the bacterium to bind to mucins and thus allowing its colonization of the gastric mucosa (41) . This action however counteracts the presumed role of TFFs as cytoprotective and so far eludes our understanding.
Since TFFs seem to contribute to organ function also outside the GI tract (like respiratory and ocular tissues, brain and neurosensory cells of the cochlea), search for further binding partners specific for the target tissue was initiated also using the before mentioned yeas-two-hybrid screen. For mouse cochlea, several candidates were detected (42) and are being studied in more details ( fig. 3 ). These new factors and their compexes with TFFs await further functional characterization as well.
TFF pharmacology and therapy
The cytoprotective nature of TFFs has been demonstrated in the GI tract and also in several other systems. It occurs that the TFFs exert their beneficial function in various ways according to the tissue they act in. Such observations suggest a possible strategy for clinical intervention. Thus applications of TFFs were considered and some of them have been even covered by patents. However, direct positive therapeutic effects were achieved upon TFF3 application in colitis ulcerosa patients (43) . While a few animal studies implied some potential in TFF adminstration, the effect might be related to the mode of TFF application and whether monomeric or dimeric forms are used. When administered luminally, TFF2 will be immobilized by the mucus layer and thus be prevented from excerting its active role (44) . In contrast, active delivery of trefoil factors by genetically modified Lactobacilli is beneficial in an acute colitis mouse model (45) but no further therapeutic studies with positive outcome have been pubished since. Outside the human and rodent systems the contribution of trefoils was analyzed in postnatal intestinal development in weaning piglets. While TFF1 did not seem to be of significance, several proteins involved in TFF regulation (e.g. EGFR, Cox-2) and TFF2 and 3 displayed increased expression levels in weaning intestinal tract. (46). If such data can become important in animal farming remains to be shown in larger and time-expanded trials.
Finally, all presently collected data on TFF function may be suggestive of one more therpeutic approach: since TFF1 and 3 in their monomeric form do not appear to bind to mucins and do not influence mucosal viscosity (as compared to TFF2 which acts effectively due to its two TFF domains) they could be applied to counteract in cases of pathologic thick mucus formation. In bronchitis, cystic fibrosis, postradiation-treatment mucositis etc.) such a potentially beneficial effect of TFF requires to be studied. However, our lack of understanding many regulatory steps in TFF biology (unknown receptors, control of coordinated expression, compensation in cases of one impaired gene sequence, further interacting factors) remains a weak basis for pharmacologic intervention.
